New drug to treat COVID-19 soon to be made available

September 20, 2021

A new treatment (Ronapreve) which is a neutralising monoclonal antibody treatment will soon be available for inpatients who meet the following criteria.

Hospitalised patients are eligible to be considered for casirivimab and imdevimab (known by its brand name Ronapreve) if:

• SARS-CoV-2 infection is confirmed by polymerase chain reaction (PCR) test or where a multidisciplinary team has a high level of confidence that the clinical and/or radiological features suggest that COVID-19 is the most likely diagnosis

AND

• Hospitalised specifically for the management of acute symptoms of COVID-19

AND

• Negative for baseline serum anti-spike (anti-S) antibodies against SARS-CoV-2

AND:

• EITHER Aged 50 and over; OR Aged 12-49 AND determined to be
immunocompromised by multi-disciplinary team assessment

Note: We are expecting the drug to be made available for our admitted patients soon. A pathway is being developed to streamline its use.